Memantin Sandoz (Memantine Hydrochloride)

Memantin Sandoz, an NMDA receptor antagonist used in neurodegenerative disease management, is indicated for:

• Alzheimer's disease (moderate to severe dementia): helps improve cognition, function, and global clinical status in adult patients.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel with moderate affinity, it blocks excessive calcium influx caused by glutamate over‑activation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission essential for learning and memory.

Memantin Sandoz may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects

• Dizziness: transient light‑headedness, especially after dose initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, may require dietary adjustment.
• Confusion: occasional disorientation, typically mild.

Serious or Rare Side Effects

• Seizures: new‑onset or worsening seizure activity.
• Allergic reactions: rash, pruritus, or angioedema requiring medical attention.
• Hallucinations: visual or auditory disturbances.
• Cardiac arrhythmias: irregular heart rhythm, particularly in patients with pre‑existing cardiac disease.

Before prescribing Memantin Sandoz, clinicians should consider several safety aspects.

• Renal impairment: assess kidney function and adjust dose if necessary.
• History of seizures: monitor closely for increased seizure frequency.
• Concurrent NMDA antagonists: avoid co‑administration to prevent additive CNS effects.
• Pregnancy: limited data; use only if potential benefit justifies potential risk.
• Elderly patients: watch for heightened confusion or falls.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantin Sandoz can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neuro‑psychiatric effects.
• Ketamine: combined CNS depression and dissociative symptoms.
• Other NMDA antagonists: risk of excessive blockade leading to severe adverse events.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may exacerbate confusion or cognitive decline.
• CNS depressants (e.g., benzodiazepines): enhanced sedation or dizziness.
• Diuretics: potential alterations in blood pressure requiring monitoring.